<DOC>
	<DOCNO>NCT01810692</DOCNO>
	<brief_summary>In COPD patient 's ability use inhaler correctly preference inhaler important factor select appropriate treatment COPD . This cross-sectional study satisfaction , preference handle two different device Respimat Breezhaler evaluate use validate PASAPQ COPD patient</brief_summary>
	<brief_title>Preference Tiotropium Respimat Study COPD</brief_title>
	<detailed_description>Purpose : Study Design :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline prior participation study conduct study procedure . 2 . Adult male female patient chronic obstructive pulmonary disease ( COPD ) less year follow usual clinical practice participant sit treatment Spiriva® Respimat® , Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler® least 3 month maximum 6 month inform consent date . Exclusion criterion : 1 . Previously include study currently participate another interventional study . 2 . Visual , cognitive , motor impairment judge investigator allow patient independently read complete questionnaire . 3 . Patients treat simultaneously respiratory medication ( Spiriva® Respimat® Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>